logo-loader

Could stock markets plunge yet further? Making sense of the current turmoil

Published: 08:08 30 Mar 2020 EDT

Goldman Sachs -

Q: How does this compare with previous cycles?

The main difference is that it’s been faster; the absolute magnitude of the falls so far is in line with many event-driven bear markets in the past. 

Q: What has been the policy response?

Swift and large. Policy has been fast to adjust this time, and we see this as a large positive and likely to prevent this from becoming systemic. 

Q: What is required to stabilize markets?

Are we there? In our view, there are four components of this: (i) A sign that the policy intervention is sufficient to prevent severe second- and third-round economic shocks; (ii) A sign that the infection rate is reaching a peak; (iii) A sign that the economic downturn may be slowing; and (iv) Cheap valuations. In reality, we believe it will be a combination of these, and in some cases there are already signs these are in place.

Q: Is this now a ‘structural’ bear market?

We don’t think so, given the policy in place. However, if this becomes systemic, (ie, rising unemployment, corporate losses infecting the banking sector and leading to a large-scale credit squeeze) then the market could have further to fall; previous structural bear markets saw the market fall by 50% or more, down another 20-25% from here. 

Q: Valuations are low, but can we trust this signal?

Valuation is a necessary but not sufficient condition for a turn; that said, on some measures and especially vs. government bonds, equities are the cheapest they have been historically. 

Q: Will this all lead to inflation?

This is a common question and, given the large policy packages delivered combined with supply chain disruptions, we believe this is a risk. However, there are also other factors that may prove ‘disinflationary’ more medium-term too, such as households’ and corporates’ desire to keep a larger cash buffer or some unwind of the inventory build in certain sectors of the economy.

Xeris Biopharma Surpasses 2023 Expectations with Strategic Moves Poised for...

Xeris Biopharma CEO Paul Edick joined Steve Darling from Proactive to share news the company had a successful 2023, with a final tally of 164 million USD, which is at the upper end of their forecast. The company concluded the year with 72 million USD in cash, surpassing their initial projections...

8 hours, 41 minutes ago